CRSP vs. KRYS, IMVT, HALO, IOVA, IBRX, SWTX, IMCR, EXEL, RVMD, and ACLX
Should you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Krystal Biotech (KRYS), Immunovant (IMVT), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), ImmunityBio (IBRX), SpringWorks Therapeutics (SWTX), Immunocore (IMCR), Exelixis (EXEL), Revolution Medicines (RVMD), and Arcellx (ACLX). These companies are all part of the "biological products, except diagnostic" industry.
CRISPR Therapeutics (NASDAQ:CRSP) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability.
CRISPR Therapeutics received 178 more outperform votes than Krystal Biotech when rated by MarketBeat users. However, 66.83% of users gave Krystal Biotech an outperform vote while only 65.61% of users gave CRISPR Therapeutics an outperform vote.
CRISPR Therapeutics' return on equity of -8.09% beat Krystal Biotech's return on equity.
CRISPR Therapeutics currently has a consensus target price of $76.29, indicating a potential upside of 43.15%. Krystal Biotech has a consensus target price of $171.00, indicating a potential upside of 8.45%. Given CRISPR Therapeutics' higher probable upside, analysts plainly believe CRISPR Therapeutics is more favorable than Krystal Biotech.
In the previous week, Krystal Biotech had 7 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 23 mentions for Krystal Biotech and 16 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.57 beat Krystal Biotech's score of 0.12 indicating that CRISPR Therapeutics is being referred to more favorably in the media.
Krystal Biotech has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 4.1% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 14.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
CRISPR Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.
Summary
Krystal Biotech beats CRISPR Therapeutics on 10 of the 17 factors compared between the two stocks.
Get CRISPR Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CRISPR Therapeutics Competitors List
Related Companies and Tools
